

# Ultrasonic Texture Analysis for Acute Myocardial Infarction Risk Stratification: A Pilot Study

Quincy A. Hathaway, MD, PhD<sup>1,2\*</sup>, Ankush D. Jamthikar, PhD<sup>1\*</sup>, Bernard R. Chaitman, MD<sup>3</sup>, Jeffery Carson, MD, MPH<sup>4</sup>, Naveena Yanamala, MS, PhD<sup>1</sup>, Partho P. Sengupta, MD, DM<sup>1</sup>

<sup>1</sup>Division of Cardiovascular Disease and Hypertension, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.

<sup>2</sup>Department of Medical Education, West Virginia University School of Medicine, Morgantown, WV, USA.

<sup>3</sup> St. Louis University School of Medicine, St. Louis, MO, USA

<sup>4</sup>Division of General Internal Medicine, Department of Medicine, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick

*Running Title: Ultrasonic Texture and Myocardial Infarction Risk Stratification*

\*Provided equal contribution to the work

## Corresponding Author

Partho P. Sengupta, MD, DM, FACC, FASE  
Rutgers Robert Wood Johnson Medical School,  
Division of Cardiovascular Disease and Hypertension,  
125 Patterson St, New Brunswick, NJ – 08901  
Phone: (646) 531-2613  
Email: [partho.sengupta@rutgers.edu](mailto:partho.sengupta@rutgers.edu)

**Word Count: 3,672**

## Abstract

**Background:** Current risk stratification tools for acute myocardial infarction (AMI) have limitations, particularly in predicting mortality. This study utilizes cardiac ultrasound radiomics (i.e., ultrasomics) to risk stratify AMI patients when predicting all-cause mortality.

**Methods:** The study included 197 patients: a) retrospective internal cohort (n=155) of non-ST-elevation myocardial infarction (n=63) and ST-elevation myocardial infarction (n=92) patients, and b) external cohort from the multicenter Door-To-Unload in ST-segment–elevation myocardial infarction [DTU-STEMI] Pilot Trial (n=42). Echocardiography images of apical 2, 3, and 4-chamber were processed through an automated deep-learning pipeline to extract ultrasomic features. Unsupervised machine learning (topological data analysis) generated AMI clusters followed by a supervised classifier to generate individual predicted probabilities. Validation included assessing the incremental value of predicted probabilities over the Global Registry of Acute Coronary Events (GRACE) risk score 2.0 to predict 1-year all-cause mortality in the internal cohort and infarct size in the external cohort.

**Results:** Three phenogroups were identified: Cluster A (high-risk), Cluster B (intermediate-risk), and Cluster C (low-risk). Cluster A patients had decreased LV ejection fraction (P=0.004) and global longitudinal strain (P=0.027) and increased mortality at 1-year (log rank P=0.049). Ultrasomics features alone (C-Index: 0.74 vs. 0.70, P=0.039) and combined with global longitudinal strain (C-Index: 0.81 vs. 0.70, P<0.001) increased prediction of mortality beyond the GRACE 2.0 score. In the DTU-

STEMI clinical trial, Cluster A was associated with larger infarcts size (>10% LV mass, P=0.003), compared to remaining clusters.

**Conclusions:** Ultrasomics-based phenogroup clustering, augmented by TDA and supervised machine learning, provides a novel approach for AMI risk stratification.

**Keywords:** Topology; TDA; Semantic Segmentation; Ultrasomics; Machine Learning

## 1 Introduction

2 Globally, acute myocardial infarction (AMI) affects nearly 10% of people over 60  
3 years of age (1). In the United States, the total annual cost of AMI was \$85 billion in  
4 2016, with an estimated \$40 billion lost due to premature mortality in the preceding  
5 decade (2). Unfortunately, despite the success of intervention and evolving guideline-  
6 directed treatment, AMI patients continue to have high morbidity and mortality (3).  
7 Currently, clinicians use validated risk stratification scoring systems, such as the Global  
8 Registry of Acute Coronary Events (GRACE) (4,5) and more recently the GRACE 2.0  
9 score (6), to predict the 6-month and 1-year risk of all-cause mortality following AMI.  
10 While guidelines have recommended using the GRACE score as the most robust model  
11 for all acute coronary syndrome types (7-9), these scores were developed using clinical  
12 trial data long before percutaneous interventions became routine. Moreover, GRACE  
13 uses conventional statistical approaches (i.e., logistic regression) with fixed linear  
14 assumptions on data behavior and limited variables, resulting in modest discrimination  
15 (e.g., C-statistic range for predicting mortality:0.65-0.8) (5,9).

16 Artificial intelligence (AI) techniques have led to the development of novel  
17 methods that includes subjecting images and other inputs to sophisticated algorithms to  
18 capture complexity of human health and disease at the level of the individual (10).  
19 These methods have achieved remarkable success, especially in disease classification  
20 and risk assessments, in several image-based disciplines, such as dermatology,  
21 gastroenterology, ophthalmology, oncology, and neuroradiology (10-16), including the  
22 development of 'omics'-based decision support tools (17-21). The application of  
23 radiomics to cardiac ultrasound (i.e., ultrasomics), may aid in risk stratification of

24 patients experiencing an AMI by extracting texture-based information from the  
25 myocardium. Moreover, the development of automated tools that integrate ultrasomics  
26 for AMI risk stratification addresses the existing gap in current guidelines which do not  
27 currently integrate cardiac imaging-based information in existing tools like GRACE 2.0  
28 for estimating risk.

29 In the present study, we used a cluster-then-predict approach for AMI risk  
30 stratification. We subjected cardiac ultrasomics information to topological data analysis  
31 (TDA)—a robust method to create compressed representations of highly dimensional  
32 data to create unique patient phenogroups (22). We illustrate that the ultrasomics  
33 phenogroups can provide independent and incremental information to conventional  
34 tools like GRACE 2.0 for augmenting 1-year mortality prediction in AMI patients.  
35 Moreover, TDA can be effectively combined with machine learning and explainable AI  
36 techniques. Accordingly, we also illustrate the ability to develop robust supervised  
37 machine-learning algorithms on clustered patients, which can be applied to external  
38 data for phenogroup prediction. Since infarct size is strongly associated with all-cause  
39 mortality in AMI (23), we used the Door-To-Unload in STEMI (DTU-STEMI) Pilot Trial  
40 (24) as an external, prospective, multicenter clinical trial cohort to illustrate that the high-  
41 risk phenogroup had larger infarct size as observed on cardiac magnetic resonance  
42 (CMR) imaging.

## 43 **Materials and Methods**

### 44 *Study Population*

45 For the internal validation dataset, we identified 155 AMI patients retrospectively  
46 from electronic medical record of Robert Wood Johnson University Hospital who were  
47 admitted over a 6-month period between January 2023 to July 2023. The Institutional  
48 Review Board (IRB) of Robert Wood Johnson University Hospital gave ethical approval  
49 for this work (#Pro2023001660).

50 This included 87 patients classified as having a NSTEMI (non-ST-elevation  
51 myocardial infarction) and 121 as having a STEMI (ST-elevation myocardial infarction).  
52 STEMI was classified per the Joint ESC/ACCF/AHA/WHF Task Force (25). Briefly, this  
53 included ECG changes revealing 1) new ST-segment elevation in 2 contiguous leads  
54 with greater than 0.1 mV in all leads, with the exception of V2 or V3, 2) new ST-  
55 segment elevation in leads V2-V3 greater than 0.2 mV (men > 40 years old), 0.25 mV  
56 (men < 40 years old), or 0.15 mV (women), 3) Pre-existing left bundle branch block  
57 were further evaluated using the Sgarbossa's criteria (26,27). Exclusion criteria included  
58 (1) patients discharged to institutionalized care, (2) type 2-5 acute myocardial infarction  
59 (AMI), (3) co-existing terminal illness such as cancer, (4) alternative diagnosis for  
60 elevated cardiac troponin values (e.g. myocarditis, pericarditis, non-ischemic  
61 cardiomyopathies, moderate-severe valvular heart disease), (5) pregnancy, and (6)  
62 technically insufficient imaging for 2 of the following 3 views: apical 4 chamber (A4C),  
63 apical 3 chamber (A3C), and apical 2 chamber (A2C). Of the 208 patients initially  
64 enrolled, 53 patients were accordingly excluded from analysis, this included patients

65 with NSTEMI (n=24) and STEMI (n=29). We assessed the performance of the GRACE  
66 2.0 score (6) with the primary outcome of all-cause mortality at one year.

67 For the external validation dataset, participants were recruited from a  
68 prospective, multicenter, randomized DTU-STEMI pilot trial (24). We included 42  
69 participants with CMR data in the current study. Briefly, patients were included in the  
70 original randomized pilot trial if they 1) were between 21 and 80 years of age and 2)  
71 presented with 1-6 hours of chest pain with documented ST-segment elevation of  $\geq 2$   
72 mm in  $\geq 2$  contiguous anterior leads or  $\geq 4$  mm total ST-segment deviation sum in the  
73 anterior leads. Patients were excluded if they had prior AMI, coronary artery bypass  
74 grafting surgery, out-of-hospital cardiac arrest requiring cardiopulmonary resuscitation,  
75 cardiogenic shock, inability to undergo Impella CP insertion, fibrinolysis within 72 hours  
76 of presentation, or contraindications to CMR imaging (24).

77 For the external validation study infarct size on CMR was used as the primary  
78 end point. CMR-quantified infarct size was categorized as large (LGE mass accounting  
79 for  $>10\%$  of the total LV mass) or small (LGE mass accounts for  $\leq 10\%$  of the total LV  
80 mass) (28,29). The details of the CMR protocol have been previously described (24).  
81 Briefly, patients in the DTU-STEMI trial underwent standard CMR with steady-state free-  
82 precession sequence for LV ejection fraction, volumes, and mass analysis on days 3 to  
83 5 and again on day 30 ( $\pm 7$  days). Delayed-enhancement imaging was performed using  
84 a 2-dimensional segmented inversion-recovery sequence, 10 minutes after  
85 administration of routine extracellular gadolinium contrast (0.15 mmol/kg of body  
86 weight). Infarct size was expressed as a percentage of total LV mass. A central core  
87 laboratory (Duke Cardiovascular Magnetic Resonance Center, Durham, NC) qualified

88 participating sites, performed quality assessment on the images during the conduct of  
89 the study, and manually performed assessment of CMR parameters on deidentified  
90 images without knowledge or access to treatment assignment or clinical outcomes. For  
91 the external cohort, institutional review boards at each site approved the trial, and  
92 patients provided written, informed consent. The study was approved by the Food and  
93 Drug Administration (NCT03000270).

94

#### 95 *Echocardiography Image Acquisition, Preprocessing, and Semantic Segmentation*

96 Echocardiograms from A4C, A3C, and A2C were utilized in the present studies  
97 for both the internal and external validation data analysis. Patients and participants  
98 required at least two of the three views to be present to be included in the current study  
99 (see *Materials and Methods, section Study Population*). 2D echocardiograms were  
100 preprocessed from video formats to DICOM using Sante DICOM Viewer Pro (SanteSoft,  
101 Nicosia, Cyprus, Greece). DICOM files containing doppler data, dual ultrasound  
102 regions, or other with limited technical views were discarded. A4C, A3C, and A2C multi-  
103 beat echocardiogram DICOM files were manually selected. Using echocv (30) (i.e., a  
104 semantic segmentation algorithm that automatically defines regions of the heart in  
105 echocardiography images through convolutional neural networks (CNNs)) were  
106 segmented the region of the left ventricle (LV) in the A4C, A3C, and A2C views.

107 Compared to the published version of the algorithm, we modified echocv to be  
108 executed using Python 3.2 and leveraged TensorFlow 1.15.0 with GPU support,  
109 alongside CUDA 10.0. The segmented images were also uniformly resized to a fixed  
110 shape of 1024 by 1024 to ensure consistency across various image sources. Otherwise



111 the use of algorithm and its validation has previously been published, specifically for  
112 predicting LV remodeling in parasternal long axis echocardiograms (31).Using the  
113 semantic segmentation algorithm, a binary mask representing the region of interest  
114 (ROI) within the A4C, A3C, and A2C views was achieved (**Figure S1A**). The ROI for  
115 each of the three views was then processed to obtained radiomics/ultrasomics-based  
116 information.

117

### 118 *Texture-based Feature Extraction*

119 Echocardiography ultrasomics were extracted in Python (v3.7.13) using  
120 pyradiomics (v3.0.1) (32), SimpleITK (v2.2.0) (33), pywavelets (v1.3.0), and numpy  
121 (v1.21.5) for both the internal and external validation sets. We have previously  
122 published using this methodology on the LV (31). Briefly, feature extraction was  
123 performed for the 2D ROI using featureextractor() from pyradiomics. Default parameters  
124 for extraction, binwidth, resampled pixel spacing, interpolator, label definition, were  
125 applied. In total, first-order (n=18), shape (n=9), and texture-based (n=73) features were  
126 extracted for each of the echocardiography views (i.e., A4C, A3C, and A2C) (**Figure**  
127 **S1B**).

128

### 129 *Topological Data Analysis (TDA)*

130 The online tool TDAView (34) was used for phenogroup cluster of AMI patients in  
131 the internal validation set. TDAView utilizes the Mapper algorithm for TDA. A 1D Mapper  
132 filter was applied using Euclidean distance. Number of intervals was defined as 10, with  
133 5 bins. To reduce the overlap between clusters, a 5% overlap was defined. The number

134 of clusters was not fixed. Based on the parameters used in TDAView, three clusters  
135 were generated, labeled as Cluster A (n=62), B (n=43), and C (n=50).

136

### 137 *Supervised Machine Learning Classifier*

138 BigML (<https://bigml.com>. BigML, Inc. Corvallis, Oregon, USA) was utilized for  
139 supervised machine learning and to develop a classifier for prediction of patients in  
140 Cluster A, B, and C. Weights were applied to Cluster A (weight=1), Cluster B  
141 (weight=1.189), and Cluster C (weight=1.023) to address class imbalance. Through the  
142 OptiML application (i.e., a supervised machine learning algorithm that compares  
143 generated ensembles, deep neural networks, and logistic regression algorithms) 10-fold  
144 cross validation was performed and prediction of Cluster A, B, and C phenogroups was  
145 performed using only ultrasomics features. Once the model was developed, batch  
146 prediction was performed on the external validation set (n=42 participants) to assign  
147 phenogroup information.

148

### 149 *Data Availability*

150 All code is made freely available on our GitHub repository  
151 [https://github.com/qahathaway/AMI\\_Phenogroups](https://github.com/qahathaway/AMI_Phenogroups). All data is available by reasonable  
152 request.

153

### 154 *Statistics*

155 GraphPad Prism (v10.1.1) and R (v4.1.0) were used for statistical analyses. The  
156 Shapiro-Wilk test assessed normality. In normally distributed data with continuous

157 variables, a two-sided Student's t-test was applied. In non-Gaussian distributed data,  
158 the Mann-Whitney test was used. When assessing more than one group of continuous  
159 variables, a one-way analysis of variance (ANOVA) was applied. A Dunnett's multiple  
160 comparisons test was used for multiple comparisons in the one-way ANOVA. When  
161 assessing more than one group of categorical variables, a non-parametric Kruskal-  
162 Wallis test was applied with multiple comparisons testing.

163 Receiver operating characteristics (ROC) area under the curve (AUC) was  
164 created using the BigML platform, utilizing 10-fold cross validation. A Kaplan-Meier  
165 curve was generated using the R packages survival (v3.4-0) (35) and survminer  
166 (v0.4.9). Stratification of events, assessed as patients at risk for mortality at one year,  
167 was performed over 50-day increments for patients in Cluster A, Cluster B, and Cluster  
168 C. The *P*-value was calculated using the log-rank test in R. Using the survival package,  
169 a Cox Proportional Hazard model (CoxPH) for time-to-event analyses of mortality at one  
170 year was assessed. A risk score was generated with the A) GRACE 2.0 score alone, B)  
171 GRACE + Cluster A, C) GRACE + LV global longitudinal strain, and D) using all three  
172 variables through CoxPH regression. A probability score (i.e., ranging from 0 to 1) for  
173 predicting outcomes was generated using the predictRisk function of the riskRegression  
174 (v2022.11.28) package in R. The concordance index (C-statistic) was calculated using  
175 the pec (v2022.05.04) package in R (36).

## 176 **Results**

### 177 *Study Overview*

178 The current study utilizes an internal validation group of acute myocardial  
179 infarction (AMI) patients (n=155) presenting with non-ST-elevation myocardial infarction  
180 (NSTEMI) and ST-elevation myocardial infarction (STEMI). Apical 4-chamber (A4C),  
181 apical 3-chamber (A3C), and apical 2-chamber (A2C) views were utilized (**Figure 2A**).  
182 Using echocardiography-derived ultrasomics, phenogroups were labeled through TDA  
183 and applied to the prediction of clinical outcomes, such as time-to-event mortality  
184 (**Figure 2B**). A supervised machine learning algorithm was further used to characterize  
185 which radiomics features are important in prediction of the phenogroups and generation  
186 of risk prediction score. We then evaluated the incremental value of the phenogroups  
187 using the internal validation group and explored how assigned phenogroup labels  
188 contributed to predicting CMR findings in the external validation group (**Figure 2C**).

189

### 190 *Patient Demographics and Functional Parameters – Internal Validation*

191 Demographic features for patients in the internal validation study presenting with  
192 NSTEMI (n=63) and STEMI (n=92) were assessed (**Table 1**). Patients presenting with  
193 STEMI were more likely to have a history of congestive heart failure (CHF) (20.65% vs.  
194 1.59%,  $P=0.0004$ ) and higher Global Registry of Acute Coronary Events (GRACE)  
195 Score (120.63 vs. 107.92,  $P=0.0184$ ), compared to NSTEMI patients, respectively.  
196 Patients presenting with NSTEMI were more likely to have a history of coronary artery  
197 disease (CAD) (52.38% vs. 19.57%,  $P<0.0001$ ), chronic kidney disease (CKD) (23.81%  
198 vs. 10.87%,  $P=0.0315$ ), and stroke (17.46% vs. 6.52%,  $P=0.0324$ ), compared to STEMI

199 patients, respectively. When comparing the groups based on type of AMI, there were no  
200 differences in outcomes, including major adverse cardiac events (MACE) at 30 days  
201 (P=0.3803), cardiovascular death at 1 year (P=0.8910), and all-cause mortality at 1 year  
202 (0.9502).

203 Echocardiographic functional features for patients in the internal validation study  
204 presenting with NSTEMI (n=63) and STEMI (n=92) were assessed (**Table 2**). Patients  
205 presenting with STEMI were more likely to have a LV ejection fraction (48% vs. 53%,  
206 P=0.0087) and left atrial end-systolic volume index (23 mL/m<sup>2</sup> vs. 29 mL/m<sup>2</sup>, P=0.0024),  
207 compared to NSTEMI patients, respectively. Further the LV wall motion score index (2  
208 vs. 1.7, P=0.0072) and LV global longitudinal strain (-11.86 vs. -14.1, P=0.0015)  
209 indicated greater wall motion abnormalities in STEMI compared to NSTEMI patients,  
210 respectively.

211

### 212 *Phenogroup Clustering through Topological Data Analysis (TDA)*

213 Ultrasomics features were collected from the following echocardiography views:  
214 A4C, A3C, and A2C (**Figure 1A-B**). To understand if these features have value in  
215 predicting outcomes in patients presenting with AMI, ultrasomics features alone were  
216 evaluated using a TDA clustering algorithm that employed Mapper. Using the online tool  
217 TDAView, three phenogroups were identified: Cluster A (n=62), Cluster B (n=43), and  
218 Cluster C (n=50) (**Figure 2**). Of these phenogroups, Cluster A and Cluster B are  
219 illustrated to be more homogenous in their connectivity within groups, whereas Cluster  
220 C is illustrated to represent a more heterogenous compilation of patients.

221 Assessing the differences between these clusters, Cluster A contains more  
222 patients with a prior history of CHF (22.58% vs. 8%,  $P=0.0397$ ), compared to Cluster C  
223 (**Table 3**). Further, the Cluster A phenogroup has a higher risk of all-cause mortality at 1  
224 year (19.35% vs. 4%,  $P=0.0308$ ), compared to Cluster C. The data in Table 2 highlight  
225 how the Cluster A represents a “high-risk” phenogroup, whereas Cluster B can be seen  
226 as “intermediate-risk” and Cluster C as “low-risk”. When assessing the  
227 echocardiographic functional parameters (**Table 4**), Cluster A had a reduced LV ejection  
228 fraction (45 vs. 53,  $P=0.0040$ ) and LV global longitudinal strain (-11.88 vs. 13.87,  
229  $P=0.0273$ ) compared to Cluster C, respectively.

230

### 231 *Supervised Machine Learning Classifier for Phenogroups*

232 To establish individual patient-level probabilities to belong to specific  
233 phenogroups, a supervised machine learning classifier was developed using the online  
234 tool BigML with their OptiML application (i.e., mixed supervised model with 10-fold cross  
235 validation) on the internal validation patients. Using only ultrasomics features, the  
236 phenogroup labels were predicted for Cluster A (ROC AUC: 0.95), Cluster B (ROC AUC:  
237 0.95), and Cluster C (ROC AUC: 0.92) (**Figure 3A**). When looking at the features  
238 contributing to the model, there was a mix of texture-based features and first order  
239 features (**Figure 3B**). Prediction probabilities were generated for the internal validation  
240 dataset based on the supervised classifier; these probabilities were used in subsequent  
241 analyses for risk prediction.

242

### 243 *Outcome Prediction in the Internal and External Patient Groups*

244 Using mortality at one year, survival analysis revealed that patients assigned to  
245 Cluster A had a significant increase in mortality compared to Cluster C (log rank,  
246  $P=0.0489$ ) (**Figure 4A**). We further wanted to further understand if the phenogroups,  
247 represented by changes in ultrasomics, had incremental value when predicting  
248 mortality. The concordance index was calculated for our four groups of variables: A)  
249 GRACE 2.0 score alone, B) GRACE + Cluster A, C) GRACE + LV global longitudinal  
250 strain, and D) using all three variables together (**Figure 4B**). We further illustrate that  
251 the use of ultrasomics alone (Concordance: 0.74 vs. 0.70,  $P=0.0395$ ), and in  
252 combination with functional echocardiographic markers (Concordance: 0.81 vs. 0.70,  
253  $P<0.0001$ ), can increase prediction of all-cause mortality beyond that of the GRACE 2.0  
254 score, respectively.

255 The developed supervised model was further applied to the external participants  
256 to assign phenogroup labels (i.e., Cluster A, B, and C). The batch prediction of the  
257 external dataset ( $n=42$  presenting with STEMI) labeled participants into Cluster A  
258 ( $n=11$ ), Cluster B ( $n=23$ ), and Cluster C ( $n=8$ ) (**Table 5**). Patients in Cluster A had a  
259 higher percentage of LV identified as “at risk” (60% vs. 37%,  $P=0.04$ ) at 5 days post  
260 AMI, compared to Cluster C. Moreover, patients in the Cluster A phenogroup had a  
261 higher proportion of large infarcts ( $>10\%$  of LV mass) at 30 days following AMI (0.91 vs.  
262 0.25,  $P=0.007$ ), when compared to Cluster C.

## 263 Discussion

264 Properties of pathological changes within the myocardial microstructure influence  
265 ultrasound signal intensity distributions (31). Unlike information obtained indirectly (i.e.,  
266 clinical risk factors, ECG, and biomarkers), specific analyzable trends in ultrasound  
267 texture information may have added insights into causal pathways that result in disease  
268 and clinical presentation. Integrating myocardial texture analysis (i.e., ultrasomics) with  
269 clinical data can provide a rich opportunity to develop machine learning models to  
270 predict adverse cardiac events following AMI. To this end we provide a proof-of-concept  
271 application of ultrasomics (i.e., cardiac ultrasound radiomics) in risk stratifying AMI  
272 patients. Three AMI phenogroups were identified according to ultrasound texture  
273 features with patients in phenogroup A having the worst prognosis. Phenogroup A  
274 showed incremental and independent information over GRACE 2.0 for predicting 1-year  
275 mortality after AMI. Using a cluster-then-predict framework we utilized an external hold  
276 out dataset for phenogroup prediction in which phenogroup A had large proportion of  
277 patients with moderate or large infarcts.

278 While classic supervised learning approaches require larger datasets, the  
279 cluster-then-predict methodology has the advantage of reducing bias, such as  
280 overfitting, when risk stratifying patients. Moreover this approach reduces prediction  
281 errors (37) and shows robust performance with echo-related data (38-41). Radiomics,  
282 deep learning features, 2D-echocardiography, demographic/clinical (e.g., age, sex,  
283 race, BSA, BMI, comorbidities, family history, etc.), laboratory, and biomarker data can  
284 further be added to incrementally increase the risk-stratification of these phenogroups.  
285 Our group has previously utilized TDA to create patient similarity networks to identify



286 aortic stenosis (42), diastolic dysfunction (43-45), and heart failure (46,47). In aortic  
287 stenosis, by creating patient phenogroups for mild and severe aortic stenosis, the “high-  
288 risk” severe aortic stenosis phenogroup was associated with increased risk of balloon  
289 valvuloplasty, and valve replacement (42). Specifically, as shown in this study, the  
290 phenotypic groups from TDA (or unsupervised machine learning, PCA clustering, etc.)  
291 can serve as class labels for developing supervised algorithms. This technique, first  
292 clustering and then predicting using supervised machine-learning models, can result in  
293 stronger associations with clinical outcomes by increasing the number of events (i.e.,  
294 phenogroup clusters) and reduce class imbalance.

295 Current risk stratification tools for AMI, such as the GRACE Score, reduce  
296 mortality rates compared to standard strategies (48,49) but, with the use of current AI  
297 applications, it is possible to characterize more patients at-risk for morbidity and  
298 mortality by combining information from clinical, laboratory, imaging, and other features.  
299 Risk stratification tools can be benchmarked using AUC and C-Index as metrics, with  
300 values ranging from 0.6-0.7 having limited clinical value, whereas those between 0.7-  
301 0.8, 0.8-0.9, and >0.9 considered to have fair, good, and excellent discrimination (50-  
302 52), respectively. The GRACE model has shown performances ranging from 0.65-0.8  
303 (C-Index) (9), with our current study reporting a performance of 0.70, utilizing the  
304 GRACE 2.0 score. We also showed how the C-Index improved when using ultrasomics  
305 features (0.74) and in combination with LV functional parameters (0.81). As this is a pilot  
306 study, future work should harness these non-clinical markers (such as ultrasomics and  
307 LV functional information) in larger, multicenter studies to create new risk stratification  
308 tools for the prediction of AMI.

309 We note several limitations to the current investigation. 1) The cohort sizes in the  
310 internal and external validations sets are relatively small (n=155 and n=42,  
311 respectively). While this patient groups are small, we highlight how the cluster-then-  
312 predict methodology is better adapted to smaller datasets and can help provide a  
313 framework for other investigations where small cohort sizes are present (i.e., rare  
314 diseases, underrepresented minorities, limited resources for data collection, etc.). 2)  
315 The outcome of interest, all-cause mortality at 1 year, was only represented in 20 of 155  
316 patients. Because of the low number of events, we used univariate analysis to screen  
317 for features to provide in the adjusted model while avoid issues with overfitting in the  
318 survival model. Nevertheless, we noted the incremental value of radiomics over  
319 conventional scores like Grace 2.0 and several echocardiographic parameters like  
320 ejection fraction, LV end-systolic volume and global longitudinal strain. Future work with  
321 larger sample size and a greater number of events would allow develop of robust  
322 multivariable models using radiomics, clinical and conventional echocardiographic  
323 features. 3) The use of TDA, and other unsupervised learning approaches, can be  
324 subjective in the number of clusters defined. In the current study, we highlight three  
325 unique phenogroups. While we could have altered the parameters to include more or  
326 less numbers of phenogroups, the main constraint on the Mapper algorithm that we  
327 wanted to maintain was a low percent overlap between groups (i.e., reducing the  
328 similarities of phenogroups and ultimately providing clearer boundaries between those  
329 with “high” and “low” risk).

330 In summary, we utilize an echocardiography-derived approach to measure  
331 ultrasomics and identify phenogroups among patients presenting with AMI. Through

332 TDA, three distinct phenogroups (Clusters A, B, and C) were delineated, with Cluster A  
333 representing a "high-risk" group, Cluster B an "intermediate-risk" group, and Cluster C a  
334 "low-risk" group. These phenogroups demonstrated significant differences in clinical  
335 outcomes, particularly in terms of all-cause mortality at 1 year. Logistic regression and  
336 supervised machine learning further validate the predictive power of these  
337 phenogroups, showing their potential utility in clinical risk stratification. Moreover,  
338 application of the developed model to an external dataset highlighted the robustness of  
339 these phenogroups in predicting cardiac magnetic resonance (CMR) findings such as  
340 infarct size, providing valuable insights for personalized patient management and  
341 prognostication in AMI.

342 **Acknowledgments**

343 None

344

345 **Sources of Funding**

346 This work was supported by: NSF: # 2125872 (PPS)

347

348 **Disclosures**

349 Dr. Sengupta is a consultant for RCE Technologies, Echo IQ. Dr. Yanamala is an

350 advisor to Turnkey Learning, LLC and Turnkey Learning (P) Ltd, Pittsburgh, PA, USA.

351 All other authors have no reported disclosures relevant to the contents of this paper to

352 disclose.

353

354 **Author Contributions**

355

356

## 357 References

- 358 1. Salari N, Morddarvanjoghi F, Abdolmaleki A et al. The global prevalence of  
359 myocardial infarction: a systematic review and meta-analysis. *BMC Cardiovasc*  
360 *Disord* 2023;23:206.
- 361 2. Bishu KG, Lekoubou A, Kirkland E et al. Estimating the Economic Burden of  
362 Acute Myocardial Infarction in the US: 12 Year National Data. *Am J Med Sci*  
363 2020;359:257-265.
- 364 3. Tsao CW, Aday AW, Almarzooq ZI et al. Heart Disease and Stroke Statistics—  
365 2022 Update: A Report From the American Heart Association. *Circulation*  
366 2022;145:e153-e639.
- 367 4. Fox KAA, Dabbous OH, Goldberg RJ et al. Prediction of risk of death and  
368 myocardial infarction in the six months after presentation with acute coronary  
369 syndrome: prospective multinational observational study (GRACE). *BMJ*  
370 2006;333:1091.
- 371 5. Eagle KA, Lim MJ, Dabbous OH et al. A Validated Prediction Model for All Forms  
372 of Acute Coronary Syndrome. *JAMA* 2004;291:2727.
- 373 6. Fox KA, Fitzgerald G, Puymirat E et al. Should patients with acute coronary  
374 disease be stratified for management according to their risk? Derivation, external  
375 validation and outcomes using the updated GRACE risk score. *BMJ Open*  
376 2014;4:e004425.
- 377 7. Collet J-P, Thiele H, Barbato E et al. 2020 ESC Guidelines for the management  
378 of acute coronary syndromes in patients presenting without persistent ST-  
379 segment elevation: The Task Force for the management of acute coronary  
380 syndromes in patients presenting without persistent ST-segment elevation of the  
381 European Society of Cardiology (ESC). *European Heart Journal* 2020;42:1289-  
382 1367.
- 383 8. Gulati M, Levy PD, Mukherjee D et al. 2021  
384 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and  
385 Diagnosis of Chest Pain: Executive Summary: A Report of the American College  
386 of Cardiology/American Heart Association Joint Committee on Clinical Practice  
387 Guidelines. *Circulation* 2021;144:e336-e367.
- 388 9. D'Ascenzo F, Biondi-Zoccai G, Moretti C et al. TIMI, GRACE and alternative risk  
389 scores in Acute Coronary Syndromes: a meta-analysis of 40 derivation studies  
390 on 216,552 patients and of 42 validation studies on 31,625 patients. *Contemp*  
391 *Clin Trials* 2012;33:507-14.
- 392 10. Rajpurkar P, Chen E, Banerjee O, Topol EJ. AI in health and medicine. *Nature*  
393 *Medicine* 2022;28:31-38.
- 394 11. Koh D-M, Papanikolaou N, Bick U et al. Artificial intelligence and machine  
395 learning in cancer imaging. *Communications Medicine* 2022;2:133.
- 396 12. Gulshan V, Peng L, Coram M et al. Development and Validation of a Deep  
397 Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus  
398 Photographs. *JAMA* 2016;316:2402-2410.
- 399 13. Huynh E, Hosny A, Guthrie C et al. Artificial intelligence in radiation oncology. *Nat*  
400 *Rev Clin Oncol* 2020;17:771-781.

- 401 14. McKinney SM, Sieniek M, Godbole V et al. International evaluation of an AI  
402 system for breast cancer screening. *Nature* 2020;577:89-94.
- 403 15. Ardila D, Kiraly AP, Bharadwaj S et al. End-to-end lung cancer screening with  
404 three-dimensional deep learning on low-dose chest computed tomography. *Nat*  
405 *Med* 2019;25:954-961.
- 406 16. Zhou D, Tian F, Tian X et al. Diagnostic evaluation of a deep learning model for  
407 optical diagnosis of colorectal cancer. *Nat Commun* 2020;11:2961.
- 408 17. Lambin P, Leijenaar RTH, Deist TM et al. Radiomics: the bridge between medical  
409 imaging and personalized medicine. *Nature Reviews Clinical Oncology*  
410 2017;14:749-762.
- 411 18. Cho H-h, Lee HY, Kim E et al. Radiomics-guided deep neural networks stratify  
412 lung adenocarcinoma prognosis from CT scans. *Communications Biology*  
413 2021;4:1286.
- 414 19. Wang Y, Yue W, Li X et al. Comparison Study of Radiomics and Deep Learning-  
415 Based Methods for Thyroid Nodules Classification Using Ultrasound Images.  
416 *IEEE Access* 2020;8:52010-52017.
- 417 20. Afshar P, Mohammadi A, Plataniotis KN, Oikonomou A, Benali H. From  
418 Handcrafted to Deep-Learning-Based Cancer Radiomics: Challenges and  
419 Opportunities. *IEEE Signal Processing Magazine* 2019;36:132-160.
- 420 21. Hunter B, Chen M, Ratnakumar P et al. A radiomics-based decision support tool  
421 improves lung cancer diagnosis in combination with the Herder score in large  
422 lung nodules. *EBioMedicine* 2022;86:104344.
- 423 22. Chazal F, Michel B. An Introduction to Topological Data Analysis: Fundamental  
424 and Practical Aspects for Data Scientists. *Front Artif Intell* 2021;4:667963.
- 425 23. Stone GW, Selker HP, Thiele H et al. Relationship Between Infarct Size and  
426 Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized  
427 Trials. *J Am Coll Cardiol* 2016;67:1674-83.
- 428 24. Kapur NK, Alkhouli MA, DeMartini TJ et al. Unloading the Left Ventricle Before  
429 Reperfusion in Patients With Anterior ST-Segment-Elevation Myocardial  
430 Infarction. *Circulation* 2019;139:337-346.
- 431 25. Thygesen K, Alpert JS, Jaffe AS et al. Third universal definition of myocardial  
432 infarction. *Eur Heart J* 2012;33:2551-67.
- 433 26. Akbar H, Foth C, Kahloon RA, Mountfort S. Acute ST-Elevation Myocardial  
434 Infarction. *StatPearls*. Treasure Island (FL) ineligible companies. Disclosure:  
435 Christopher Foth declares no relevant financial relationships with ineligible  
436 companies. Disclosure: Rehan Kahloon declares no relevant financial  
437 relationships with ineligible companies. Disclosure: Steven Mountfort declares no  
438 relevant financial relationships with ineligible companies., 2024.
- 439 27. Smith SW, Dodd KW, Henry TD, Dvorak DM, Pearce LA. Diagnosis of ST-  
440 elevation myocardial infarction in the presence of left bundle branch block with  
441 the ST-elevation to S-wave ratio in a modified Sgarbossa rule. *Ann Emerg Med*  
442 2012;60:766-76.
- 443 28. Al-Hussaini A, Abdelaty A, Gulsin GS et al. Chronic infarct size after spontaneous  
444 coronary artery dissection: implications for pathophysiology and clinical  
445 management. *Eur Heart J* 2020;41:2197-2205.

- 446 29. Krljanac G, Apostolovic S, Polovina M et al. Differences in left ventricular  
447 myocardial function and infarct size in female patients with ST elevation  
448 myocardial infarction and spontaneous coronary artery dissection. *Front*  
449 *Cardiovasc Med* 2023;10:1280605.
- 450 30. Zhang J, Gajjala S, Agrawal P et al. Fully Automated Echocardiogram  
451 Interpretation in Clinical Practice. *Circulation* 2018;138:1623-1635.
- 452 31. Hathaway QA, Yanamala N, Siva NK, Adjeroh DA, Hollander JM, Sengupta PP.  
453 Ultrasonic Texture Features for Assessing Cardiac Remodeling and Dysfunction.  
454 *J Am Coll Cardiol* 2022;80:2187-2201.
- 455 32. van Griethuysen JJM, Fedorov A, Parmar C et al. Computational Radiomics  
456 System to Decode the Radiographic Phenotype. *Cancer Res* 2017;77:e104-  
457 e107.
- 458 33. Yaniv Z, Lowekamp BC, Johnson HJ, Beare R. SimpleITK Image-Analysis  
459 Notebooks: a Collaborative Environment for Education and Reproducible  
460 Research. *Journal of Digital Imaging* 2018;31:290-303.
- 461 34. Walsh K, Voineagu MA, Vafaei F, Voineagu I. TDAview: an online visualization  
462 tool for topological data analysis. *Bioinformatics* 2020;36:4805-4809.
- 463 35. Therneau TM. A Package for Survival Analysis in R. 2022:R package version 3.4-  
464 0.
- 465 36. Mogensen UB, Ishwaran H, Gerds TA. Evaluating Random Forests for Survival  
466 Analysis using Prediction Error Curves. *J Stat Softw* 2012;50:1-23.
- 467 37. Trivedi S, Pardos ZA, Heffernan NT. The utility of clustering in prediction tasks.  
468 arXiv preprint arXiv:150906163 2015.
- 469 38. Kagiya N, Shrestha S, Cho JS et al. A low-cost texture-based pipeline for  
470 predicting myocardial tissue remodeling and fibrosis using cardiac ultrasound.  
471 *EBioMedicine* 2020;54:102726.
- 472 39. Tokodi M, Shrestha S, Bianco C et al. Interpatient similarities in cardiac function:  
473 a platform for personalized cardiovascular medicine. *Cardiovascular Imaging*  
474 2020;13:1119-1132.
- 475 40. Pandey A, Kagiya N, Yanamala N et al. Deep-learning models for the  
476 echocardiographic assessment of diastolic dysfunction. *Cardiovascular Imaging*  
477 2021;14:1887-1900.
- 478 41. Sengupta PP, Shrestha S, Kagiya N et al. A Machine-Learning Framework to  
479 Identify Distinct Phenotypes of Aortic Stenosis Severity. *JACC Cardiovasc*  
480 *Imaging* 2021;14:1707-1720.
- 481 42. Casaciang-Verzosa G, Shrestha S, Khalil MJ et al. Network Tomography for  
482 Understanding Phenotypic Presentations in Aortic Stenosis. *JACC Cardiovasc*  
483 *Imaging* 2019;12:236-248.
- 484 43. Pandey A, Kagiya N, Yanamala N et al. Deep-Learning Models for the  
485 Echocardiographic Assessment of Diastolic Dysfunction. *JACC Cardiovasc*  
486 *Imaging* 2021;14:1887-1900.
- 487 44. Shah R, Tokodi M, Jamthikar A et al. A Deep Patient-Similarity Learning  
488 Framework for the Assessment of Diastolic Dysfunction in Elderly Patients. *Eur*  
489 *Heart J Cardiovasc Imaging* 2024.



- 490 45. Tokodi M, Shrestha S, Bianco C et al. Interpatient Similarities in Cardiac  
491 Function: A Platform for Personalized Cardiovascular Medicine. *JACC*  
492 *Cardiovasc Imaging* 2020;13:1119-1132.
- 493 46. Cho JS, Shrestha S, Kagiyama N et al. A Network-Based "Phenomics" Approach  
494 for Discovering Patient Subtypes From High-Throughput Cardiac Imaging Data.  
495 *JACC Cardiovasc Imaging* 2020;13:1655-1670.
- 496 47. Patel HB, Yanamala N, Patel B et al. Electrocardiogram-Based Machine Learning  
497 Emulator Model for Predicting Novel Echocardiography-Derived Phenogroups for  
498 Cardiac Risk-Stratification: A Prospective Multicenter Cohort Study. *J Patient*  
499 *Cent Res Rev* 2022;9:98-107.
- 500 48. Hall M, Bebb OJ, Dondo TB et al. Guideline-indicated treatments and  
501 diagnostics, GRACE risk score, and survival for non-ST elevation myocardial  
502 infarction. *Eur Heart J* 2018;39:3798-3806.
- 503 49. van der Sangen NMR, Azzahhafi J, Chan Pin Yin D et al. External validation of  
504 the GRACE risk score and the risk-treatment paradox in patients with acute  
505 coronary syndrome. *Open Heart* 2022;9.
- 506 50. Ohman EM, Granger CB, Harrington RA, Lee KL. Risk stratification and  
507 therapeutic decision making in acute coronary syndromes. *JAMA* 2000;284:876-  
508 8.
- 509 51. Shann F. Are we doing a good job: PRISM, PIM and all that. *Intensive Care Med*  
510 2002;28:105-7.
- 511 52. Solomon LJ. Mortality risk prediction models: Methods of assessing  
512 discrimination and calibration and what they mean. *South Afr J Crit Care*  
513 2022;38.
- 514

515



516 **Tables and Table Legends**

517 **Table 1**

<b>Internal Validation - Patient Demographics Stratified by Acute Myocardial Infarction (AMI)</b>			
<b>Variable</b>	<b>NSTEMI (n=63)</b>	<b>STEMI (n=92)</b>	<b>P-Value</b>
Age (years)	68.03 (66.48-69.58)	65.47 (64.04-66.9)	0.28
Sex/Gender (Male)	40 (63.49%)	70 (76.09%)	0.09
Race/Ethnicity			
Caucasian	24 (38.1%)	37 (40.22%)	0.79
Asian American	8 (12.7%)	22 (23.91%)	0.08
Hispanic American	14 (22.22%)	14 (15.22%)	0.27
Black/African American	6 (9.52%)	8 (8.7%)	0.86
BMI (kg/m <sup>2</sup> )	27.82 (27.09-28.55)	28.43 (27.42-29.44)	0.67
Systolic Blood Pressure (mmHg)	143 (140-146)	143 (140-147)	0.96
Diastolic Blood Pressure (mmHg)	74 (72-75)	80 (78-82)	0.05
Heart Rate (per minute)	84 (81-86)	85 (83-87)	0.66
Cardiac Arrest (at admission)	0 (0%)	4 (4.35%)	0.09
Troponin Elevation (at admission)	63 (100%)	89 (96.74%)	0.15
Smoking History			
Current	11 (17.46%)	18 (19.57%)	0.74
Former	18 (28.57%)	22 (24.18%)	0.54
History of CHF	1 (1.59%)	19 (20.65%)	<b>*0.0004</b>
History of COPD	5 (7.94%)	2 (2.17%)	0.09
History of CAD	33 (52.38%)	18 (19.57%)	<b>*&lt;0.0001</b>
History of CKD	15 (23.81%)	10 (10.87%)	<b>*0.03</b>
History of Diabetes Mellitus	35 (55.56%)	39 (42.39%)	0.11
History of Hyperlipidemia	38 (60.32%)	51 (55.43%)	0.55
Prior Myocardial Infarction	12 (19.05%)	13 (14.29%)	0.43
Prior Percutaneous Intervention	22 (34.92%)	25 (27.17%)	0.31
Prior Coronary Artery Bypass Graft	7 (11.11%)	7 (7.61%)	0.46
Prior Stroke	11 (17.46%)	6 (6.52%)	<b>*0.03</b>
GRACE Score	107.92 (105.04-110.8)	120.63 (116.97-124.28)	<b>*0.02</b>
MACE at 30 Days	6 (9.52%)	13 (14.29%)	0.38
Cardiovascular Death - 1 year	5 (8.06%)	8 (8.7%)	0.89
All Cause Mortality - 1 year	8 (12.70%)	12 (13.04%)	0.95

518

519 **Table 1: Patient Demographics of the Internal Validation Group Stratified by Acute**

520 **Myocardial Infarction (AMI).** Patients presenting with non-ST-elevation myocardial

521 infarction (NSTEMI, n=63) and ST-elevation myocardial infarction (STEMI, n=92). The

522 Shapiro-Wilk test assessed normality. In normally distributed data with continuous  
523 variables, a two-sided Student's t-test was applied. In non-Gaussian distributed data,  
524 the Mann-Whitney test was used. Data are presented as the percent (%) of total or the  
525 95% confidence interval, where applicable. Data are considered statistically significant if  
526  $P \leq 0.05$ , denoted by \*. BMI = body mass index, CHF = congestive heart failure, COPD =  
527 chronic obstructive pulmonary disease, CAD = coronary artery disease, CKD = chronic  
528 kidney disease, GRACE = Global Registry of Acute Coronary Events, MACE = major  
529 adverse cardiac events.

530 **Table 2**

<b>Internal Validation - Patient Cardiac Function Stratified by Acute Myocardial Infarction (AMI)</b>			
<b>Variable</b>	<b>NSTEMI (n=63)</b>	<b>STEMI (n=92)</b>	<b>P-Value</b>
Left Ventricular Internal Diameter - End Diastole (mm)	46 (45-47)	47 (45-49)	0.38
Left Ventricular Internal Diameter - End Systole (mm)	34 (32-36)	37 (35-39)	0.07
Left Ventricular Mass Index (g/m <sup>2</sup> )	87 (81-93)	92 (85-98)	0.35
Left Ventricular End-diastole Volume (mL)	94 (86-103)	106 (99-113)	0.06
Left Ventricular End-systole Volume (mL)	47 (40-53)	57 (51-62)	<b>*0.03</b>
Left Ventricular Ejection Fraction (%)	53 (50-56)	48 (45-50)	<b>*0.009</b>
Left Ventricular Wall Motion Score Index	1.7 (1.56-1.83)	2 (1.9-2.11)	<b>*0.007</b>
Left Ventricular Global Longitudinal Strain (%)	-14.1 (-15.07- -13.12)	-11.86 (-12.64- -11.08)	<b>*0.002</b>
Left Ventricular Outflow Tract Stroke Volume (mL)	61 (56-66)	55 (51-59)	0.12
e' Septal	5.90 (5.47-6.33)	6.04 (5.64-6.43)	0.64
e' Lateral	8.26 (7.51-9.02)	7.79 (7.26-8.32)	0.95
Mitral Valve E Wave (cm/s)	85 (78-91)	83 (77-89)	0.81
MV-A (cm/s)	85 (79-91)	79 (74-84)	0.21
E/A Ratio	1.06 (0.94-1.18)	1.05 (0.96-1.14)	0.92
E/e' Septal	15.70 (13.71-17.69)	15.06 (13.66-16.45)	0.64
E/e' Lateral	11.57 (10.19-12.94)	11.63 (10.44-12.82)	0.95
Left Atrial End-systolic Volume Index (mL/m <sup>2</sup> )	29 (26-31)	23 (21-25)	<b>*0.002</b>

531

532 **Table 2: Patient Cardiac Function of the Internal Validation Group Stratified by**

533 **Acute Myocardial Infarction (AMI).** Patients presenting with non-ST-elevation

534 myocardial infarction (NSTEMI, n=63) and ST-elevation myocardial infarction (STEMI,

535 n=92). The Shapiro-Wilk test assessed normality. In normally distributed data with

536 continuous variables, a two-sided Student's t-test was applied. In non-Gaussian

537 distributed data, the Mann-Whitney test was used. Data are presented as the percent

538 (%) of total or the 95% confidence interval, where applicable. Data are considered

539 statistically significant if  $P \leq 0.05$ , denoted by \*.

540 **Table 3**

Internal Validation - Patient Demographics in Predicted Ultrasomics Phenogroups				
Variable	Cluster A (High Risk) (n=62)	Cluster B (n=43)	Cluster C (Low Risk) (n=50)	P-Value
Age (years)	66.74 (62.98-70.51)	66.88 (62.34-71.43)	65.9 (62.03-69.77)	0.94
Sex/Gender (Male)	44 (70.97%)	31 (72.09%)	35 (70%)	0.98
Race/Ethnicity				
Caucasian	24 (38.71%)	16 (37.21%)	21 (42%)	0.89
Asian American	12 (19.35%)	8 (18.6%)	10 (20%)	0.99
Hispanic American	9 (14.52%)	9 (20.93%)	10 (20%)	0.64
Black/African American	5 (8.065%)	4 (9.302%)	5 (10%)	0.94
BMI (kg/m <sup>2</sup> )	29.01 (26.08-31.93)	28.9 (26.91-30.89)	26.56 (24.68-28.43)	0.28
Systolic Blood Pressure (mmHg)	140 (132-149)	145 (135-155)	145 (136-155)	0.65
Diastolic Blood Pressure (mmHg)	78 (73-84)	77 (71-84)	76 (71-80)	0.72
Heart Rate (per minute)	86 (81-92)	85 (78-93)	81 (76-87)	0.47
Cardiac Arrest (at admission)	2 (3.226%)	1 (2.326%)	1 (2%)	0.92
Troponin Elevation (at admission)	61 (98.39%)	43 (100%)	48 (96%)	0.37
STEMI (at admission)	36 (58.06%)	26 (60.47%)	30 (60%)	0.96
Smoking History				
Current	16 (25.81%)	11 (25.58%)	13 (26.53%)	0.99
Former	10 (16.13%)	6 (13.95%)	13 (26%)	0.27
History of CHF	14 (22.58%)*	2 (4.651%)	4 (8%)	<b>*0.01</b>
History of COPD	1 (1.613%)	4 (9.302%)	2 (4%)	0.17
History of CAD	21 (33.87%)	18 (41.86%)	12 (24%)	0.19
History of CKD	10 (16.13%)	5 (11.63%)	10 (20%)	0.55
History of Diabetes Mellitus	30 (48.39%)	19 (44.19%)	25 (50%)	0.85
History of Hyperlipidemia	34 (54.84%)	25 (58.14%)	30 (60%)	0.86
Prior Myocardial Infarction	8 (12.9%)	10 (23.26%)	7 (14.29%)	0.34
Prior Percutaneous Intervention	5 (8.065%)	5 (11.63%)	4 (8%)	0.67
Prior Coronary Artery Bypass Graft	21 (33.87%)	13 (30.23%)	13 (26%)	0.79
Prior Stroke	6 (9.677%)	4 (9.302%)	7 (14%)	0.71
GRACE Score	118.1 (109.1-127.2)	114.5 (104.8-124.3)	112.8 (103.9-121.8)	0.69
MACE at 30 Days	7 (11.29%)	5 (11.63%)	7 (14.29%)	0.88
Cardiovascular Death - 1 year	8 (13.11%)	4 (9.302%)	1 (2%)	0.11
All Cause Mortality - 1 year	12 (19.35%)*	6 (13.95%)	2 (4%)	<b>*0.04</b>

541

542 **Table 3: Patient Demographics of the Internal Validation Group for Predicted**

543 **Ultrasomics Phenogroups.** Using only the ultrasomics features from the A4C, A3C,

544 and A2C echocardiogram views, patients were clustered into phenogroups. Cluster A  
545 “high-risk” (n=62), Cluster B “intermediate-risk” (n=43), and Cluster C “low-risk” (n=50)  
546 using topological data analysis (TDA). A one-way analysis of variance (ANOVA) was  
547 applied for continuous variables and a Dunnett’s multiple comparisons test was used for  
548 multiple comparisons. For categorical data, a non-parametric Kruskal-Wallis test was  
549 applied with multiple comparisons testing. Data are presented as the percent (%) of  
550 total or the 95% confidence interval, where applicable. Data are considered statistically  
551 significant if  $P \leq 0.05$ , denoted by \*. BMI = body mass index, CHF = congestive heart  
552 failure, COPD = chronic obstructive pulmonary disease, CAD = coronary artery disease,  
553 CKD = chronic kidney disease, STEMI = ST-elevation myocardial infarction, GRACE =  
554 Global Registry of Acute Coronary Events, MACE = major adverse cardiac events.

555 **Table 4**

<b>Internal Validation - Patient Cardiac Function in Predicted Ultrasonics Phenogroups</b>				
<b>Variable</b>	<b>Cluster A (High Risk) (n=62)</b>	<b>Cluster B (n=43)</b>	<b>Cluster C (Low Risk) (n=50)</b>	<b>P-Value</b>
Left Ventricular Internal Diameter - End Diastole (mm)	48 (46-50)	46 (43-49)	45 (43-47)	0.17
Left Ventricular Internal Diameter - End Systole (mm)	37 (35-40)*	35 (31-38)	33 (31-36)	<b>*0.04</b>
Left Ventricular Mass Index (g/m <sup>2</sup> )	92 (84-99)	85 (76-93)	91 (81-101)	0.53
Left Ventricular End-diastole Volume (mL)	103 (92-113)	108 (95-120)	95 (86-104)	0.27
Left Ventricular End-systole Volume (mL)	58 (50-66)*	52 (42-62)	46 (40-53)	0.07
Left Ventricular Ejection Fraction (%)	45 (41-49)*	54 (50-58)	53 (50-56)	<b>*0.001</b>
Left Ventricular Wall Motion Score Index	2.00 (1.83-2.17)	1.80 (1.51-2.10)	1.78 (1.61-1.96)	0.18
Left Ventricular Global Longitudinal Strain (%)	-11.88 (-12.99 - 10.78)*	-13.1 (-14.55 - 11.66)	-13.87 (-15.03 - 12.72)	<b>*0.04</b>
Left Ventricular Outflow Tract Stroke Volume (mL)	53 (48-59)*	57 (49-64)	64 (57-71)	<b>*0.04</b>
e' Septal	5.48 (5.04-5.91)*	6.12 (5.54-6.69)	6.50 (5.86-7.15)	<b>*0.02</b>
e' Lateral	7.56 (6.85-8.27)	8.54 (7.64-9.44)	8.03 (7.09-8.97)	0.25
Mitral Valve E Wave (cm/s)	82 (75-90)	83 (72-93)	87 (78-95)	0.74
MV-A (cm/s)	81 (74-89)	79 (69-88)	86 (77-94)	0.52
E/A Ratio	1.06 (0.928-1.19)	1.05 (0.899-1.21)	1.06 (0.886-1.22)	0.99
E/e' Septal	16.51 (14.45-18.58)	14.64 (11.6-17.67)	14.28 (12.43-16.12)	0.30
E/e' Lateral	12.10 (10.48-13.72)	10.91 (8.86-12.96)	11.58 (9.83-13.34)	0.63
Left Atrial End-systolic Volume Index (mL/m <sup>2</sup> )	26 (24-29)	23 (20-26)	25 (21-29)	0.39

556

557 **Table 4: Patient Cardiac Function of the Internal Validation Group for Predicted**  
 558 **Ultrasonics Phenogroups.** Using only the ultrasonics features from the A4C, A3C,  
 559 and A2C echocardiogram views, patients were clustered into phenogroups. Cluster A  
 560 “high-risk” (n=62), Cluster B “intermediate-risk” (n=43), and Cluster C “low-risk” (n=50)  
 561 using topological data analysis (TDA). A one-way analysis of variance (ANOVA) was  
 562 applied for continuous variables and a Dunnett’s multiple comparisons test was used for

563 multiple comparisons. For categorical data, a non-parametric Kruskal-Wallis test was  
564 applied with multiple comparisons testing. Data are presented as the percent (%) of  
565 total or the 95% confidence interval, where applicable. Data are considered statistically  
566 significant if  $P \leq 0.05$ , denoted by \*.

567 **Table 5**

<b>External Validation - Patient Demographics in Predicted Ultrasonics Phenogroups</b>				
<b>Variable</b>	<b>Cluster A (High Risk) (n=11)</b>	<b>Cluster B (n=23)</b>	<b>Cluster C (Low Risk) (n=8)</b>	<b>P-Value</b>
Age (years)	56.82 (48.07-65.57)	58.26 (53.72-62.8)	62.88 (54.99-70.76)	0.48
Sex/Gender (Male)	9 (81.82%)	18 (78.26%)	5 (62.5%)	0.60
Race/Ethnicity				
Caucasian	8 (72.73%)	17 (73.91%)	6 (75%)	0.99
Asian American	1 (9.091%)	3 (13.04%)	0 (0%)	0.58
Hispanic American	0 (0%)	1 (4.545%)	0 (0%)	0.66
Black/African American	1 (9.09%)	3 (13.04%)	2 (25%)	0.62
BMI (kg/m <sup>2</sup> )	30.08 (25.73-34.42)	31.61 (27.35-35.88)	25.61 (21.55-29.67)	0.23
Systolic Blood Pressure (mmHg)	148 (129-167)	158 (143-173)	144 (132-157)	0.44
Diastolic Blood Pressure (mmHg)	93 (81-104)	91 (84-99)	87 (75-99)	0.71
Heart Rate (per minute)	85 (77-93)	91 (81-101)	81 (66-96)	0.45
Left Ventricular Ejection Fraction (%)	36 (27-45)	37 (31-43)	44 (37-51)	0.41
Mitral Valve E Wave (cm/s)	74 (58-91)	77 (69-0.85)	74 (60-89)	0.93
Mitral Valve A Wave (cm/s)	72 (62-83)	69 (59-78)	74 (64-85)	0.71
E/A Ratio	1.07 (0.78-1.37)	1.20 (0.98-1.42)	1.02 (0.79-1.24)	0.55
History of COPD	0 (0%)	0 (0%)	0 (0%)	0.99
History of CAD	1 (9.091%)	1 (4.348%)	1 (12.5%)	0.73
History of CKD	0 (0%)	0 (0%)	0 (0%)	0.99
History of Diabetes Mellitus	3 (27.27%)	4 (17.39%)	0 (0%)	0.30
History of Hyperlipidemia	7 (63.64%)	9 (39.13%)	4 (50%)	0.42
Prior Stroke	1 (9.091%)	0 (0%)	0 (0%)	0.25
MACE - 30 Days	0 (0%)	2 (8.696%)	0 (0%)	0.44
Cardiovascular Death - 30 Days	0 (0%)	0 (0%)	0 (0%)	0.99
All Cause Mortality - 30 Days	0 (0%)	0 (0%)	0 (0%)	0.99
Infarct Size (%) of Area at Risk - 5 Days	60 (52-68)*	46 (37-56)	37 (18-56)	0.06
Acute Volume of Infarct Size (mL) - 5 Days	43 (32-54)	31 (20-42)	21 (-4.12-46)	0.17
Acute Infarct Size (%) of LV Mass - 5 Days	23 (17-29)	17 (11-23)	12 (-0.53-25)	0.24
Acute Infarct Size >10% of LV Mass - 5 Days	9 (82%)	14 (61%)	3 (38%)	0.07
Acute Volume of Infarct Size (mL) - 30 Days	28 (21-36)	23 (14-32)	14 (-3.10-31)	0.25
Acute Infarct Size (%) of LV Mass - 30 Days	18 (13-22)	14 (8.73-19)	9.23 (-1.31-20)	0.27
Acute Infarct Size >10% of LV Mass - 30 Days	10 (91%)	11 (48%)	2 (25%)	<b>*0.008</b>



568

569 **Table 5: Patient Demographics of the External Validation Group for Predicted**  
570 **Ultrasonics Phenogroups.** Using the supervised machine learning classifier  
571 developed on the internal validation cohort, class labels were generated for the external  
572 hold out dataset (i.e., the prospective, multicenter, randomized DTU-STEMI pilot trial  
573 dataset) using batch prediction in BigML. Labels were applied based solely on  
574 ultrasonics features from the A4C, A3C, and A2C echocardiogram views. A one-way  
575 analysis of variance (ANOVA) was applied for continuous variables and a Dunnett's  
576 multiple comparisons test was used for multiple comparisons. For categorical data, a  
577 non-parametric Kruskal-Wallis test was applied with multiple comparisons testing. Data  
578 are considered statistically significant if  $P \leq 0.05$ , denoted by \*. BMI = body mass index,  
579 CHF = congestive heart failure, COPD = chronic obstructive pulmonary disease, CAD =  
580 coronary artery disease, CKD = chronic kidney disease, MACE = major adverse cardiac  
581 events, LV = left ventricular.

582 **Figure and Figure Legends**

583 **Figure 1: Study Design and Overview.** (A) The internal validation patient cohort  
584 included patients with presenting with non-ST-elevation myocardial infarction (NSTEMI,  
585 n=63) and ST-elevation myocardial infarction (STEMI, n=92) who underwent  
586 echocardiography with views of the Apical 2-Chamber (A2C), Apical 3-Chamber (A3C),  
587 and Apical 4-Chamber (A4C). (B) Ultrasomics features were extracted using echocv  
588 and pyradiomics (v3.0.1). TDAView was used to cluster patients into three  
589 phenogroups: Cluster A, Cluster B, and Cluster C. The identified phenogroups were  
590 used to develop individual patient predicted probability of cluster assignment using a  
591 supervised machine learning classifier. (C) The generated probabilities from the  
592 supervised classifier were used to predict mortality and illustrate the incremental value  
593 of ultrasomics features over GRACE 2.0. Ultrasomics features were also extracted from  
594 the external validation group and applied to the supervised machine learning classifier  
595 to produce class labels (i.e., Cluster A, B, and C). The external validation phenogroups  
596 were used to predict findings on cardiac magnetic resonance, including acute infarct  
597 size.

598 **Figure 2: Topological Data Analysis (TDA) Clustering of Ultrasomics Features.**



599 Using TDAView a 1D Mapper filter was applied using Euclidean distance. Number of  
600 intervals was defined as 10, with 5 bins. To reduce the overlap between clusters, a 5%  
601 overlap was defined. Individual nodes are represented as red circles, with the number  
602 next to the node corresponding to the number of patients included in the node. Cluster A  
603 (n=62), Cluster B (n=43), and Cluster C (n=50).

604 **Figure 3: Supervised Machine Learning Classifier.** (A) Ultrasomics features, as well  
605 as the class label for the topological data analysis (TDA)-defined phenogroups, were  
606 assessed using BigML and OptiML through 10-fold cross validation in the internal  
607 validation data. (B) The top five features contributing to model development for the  
608 supervised machine learning classifier.

609 **Figure 4: Performance of Phenogroups in Assessing All-Cause Mortality. (A)**  
610 Kaplan Meyer curve and stratified risk categories for patients in phenogroups Cluster A,  
611 Cluster B, and Cluster C. **(B)** Time-to-event Concordance Index (C-Index) for groups A)  
612 GRACE 2.0 score alone, B) GRACE + Cluster A, C) GRACE + left ventricular global  
613 longitudinal strain (GLS), and D) using all three variables through CoxPH regression.  
614 **(C)** Incremental value of ultrasomics features (i.e., Cluster A) in predicting all-cause  
615 mortality. GRACE = Global Registry of Acute Coronary Events.



# A) Image



Automated Selection / Segmentation

# B) Combined TDA/Supervised Machine Learning

Feature Extraction

## Ultrasonomics

A2C (n=122) A3C (n=142) A4C (n=155)

1<sup>st</sup> order (n=18)

(e.g.) Mean  
Median  
Range

Shape-based (n=9)


(e.g.) Perimeter  
Area  
Elongation

Texture-based (n=73)

GLCM GLDM  
GLRLM NGTDM  
GLSZM

# C) Analysis and Validation


## Prediction Probabilities




### External

Predict Large Infarct

## Phenotyping




## Outcome Analysis



Demographics  
Clinical Data  
+  
Standard Echo  
Variables  
+  
Phenogroups  
Probability

Supervised Classifier  
to Predict Mortality  
at 1 year






**Cluster C**


**Cluster B**

**Cluster A**





**A****B**

### Feature Importance








medRxiv preprint doi: <https://doi.org/10.1101/2024.03.26.24044831>; this version posted March 27, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

**Strata**










Number at Risk (%)

	0	73	146	219	292	365
Cluster C	50 (100)	50 (100)	50 (100)	48 (96)	48 (96)	48 (96)
Cluster B	43 (100)	42 (98)	40 (93)	39 (91)	39 (91)	38 (88)
Cluster A	62 (100)	54 (87)	52 (84)	52 (84)	51 (82)	51 (82)

Time in days





**A****A2C****A3C****A4C****B**1<sup>st</sup> order (n=18)

(e.g.)  
Mean  
Median  
Range

Shape-based (n=9)

(e.g.)  
Perimeter  
Area  
Elongation

Texture-based (n=73)

GLCM  
GLRLM  
GLSZM  
GLDM  
NGTDM